What Tebofortin Treats: Main Uses and Benefits

Tebofortin contains Ginkgo biloba extract. The therapeutic relevance of the extract is recognized across three main symptomatic areas. The medication is applied in situations involving certain distressing symptoms, generally across three domains: age-related cognitive decline, discomfort linked to peripheral circulation, and circulation-related sensory manifestations. It is often applied during phases when symptoms become more noticeable, providing support that helps ease the overall symptom burden.

“It may assist with maintaining a sense of stability when symptoms interfere with routine activities.”

Quick Fact: Relief for Dizziness and Ringing

Quick Fact: Relief for Vertigo and Tinnitus

By addressing these symptom clusters, Tebofortin contributes to easing the overall symptom load and assists patients with coping more steadily with symptomatic periods when chronic discomfort is present.

Regulatory References

1. European Medicines Agency (EMA) Herbal Monograph

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults (18 years and older) and the Elderly population.
Populations for whom use is not recommended	Children and adolescents under 18 years of age (due to insufficient data).
Populations for whom use is contraindicated	Patients with known hypersensitivity to Ginkgo preparations or any excipients (e.g., soya).
Pregnancy and lactation eligibility	Contraindicated in Pregnancy. Use is not recommended during Lactation.

Eligibility Classifications

Classification	Official Regulatory Status
Eligibility severity classification	Contraindicated, Not Recommended, Use with Caution.
Eligibility-context constraints	Lack of sufficient data to establish use in children. Prohibition tied to potential effect on blood coagulation.

Resulting Eligibility Structure

Official eligibility statements:

• The medicine is contraindicated in pregnant women and those with an allergy to its active substance or specific excipients.
• Use is not recommended for children, adolescents, or women who are breastfeeding.
• Caution is required for patients with a pathologically increased bleeding tendency (haemorrhagic diathesis) or epilepsy.
• The product must be discontinued at least two weeks prior to any scheduled surgical or dental procedure.

Connection to the overall eligibility profile: Official regulatory documents classify the eligible population for Tebofortin as adults and the elderly. Non-eligibility rules are determined by formal contraindications against use in pregnancy and hypersensitivity, and an official determination that data are insufficient to recommend the product for the pediatric population.

Interactions with other medicines and products

The active ingredient in Tebofortin, a standardized Ginkgo biloba extract (EGb 761), has documented interaction potential with several medicinal products through both pharmacodynamic and pharmacokinetic mechanisms.

Clinically Significant Interactions

Interacting Product Category	Example Medicines	Interaction Mechanism & Effect
Anticoagulants and Antiplatelets	Warfarin, Clopidogrel, Acetylsalicylic acid (Aspirin), NSAIDs	Potential for increased risk of bleeding. Though clinical studies with EGb 761 and Warfarin have not consistently shown an effect, caution and patient monitoring are advised.
HIV Antivirals	Efavirenz	CYP3A4 enzyme induction may occur, which can lead to decreased plasma concentrations and reduced effectiveness of the antiviral. Concomitant use is generally not recommended.
Calcium Channel Blockers	Nifedipine	May lead to increased plasma concentrations of Nifedipine, potentially causing increased severity of side effects such as dizziness and hot flushes.
P-glycoprotein (P-gp) Substrates	Dabigatran etexilate	Inhibition of P-glycoprotein in the intestine may increase the exposure and concentration of Dabigatran, requiring caution.
Seizure Threshold-Lowering Drugs	Anticonvulsants	A risk of increased seizure susceptibility cannot be ruled out, requiring caution for patients with epilepsy or those taking medications that lower the seizure threshold.

Procedural and Timing Constraints

Due to the potential influence on blood clotting, the medicinal product should be discontinued as a precaution 3 to 4 days prior to any planned surgical procedure to reduce the risk of excessive bleeding.

Vascular Hemodynamic and Rheological Modulation

This domain involves the active components regulating blood vessel tone and the properties of blood flow, primarily in the microcirculation. The terpene lactones, particularly Ginkgolide B, act as selective antagonists of the Platelet-Activating Factor (PAF) receptor , a key mediator of platelet aggregation and microvascular constriction. Concurrently, the extract promotes the release of Nitric Oxide (NO) from the endothelium. These mechanisms facilitate vasodilation and modify the fluidity of blood, leading to enhanced tissue perfusion in the capillary networks of the brain and periphery.

---

Cellular Protection and Anti-Oxidative Mechanism

This mechanistic domain focuses on mitigating the processes that cause damage to cellular structures susceptible to metabolic stress. The flavonol glycosides function as direct free radical scavengers, neutralizing Reactive Oxygen Species (ROS). By limiting this oxidative stress cascade, the mechanism contributes to the stabilization of neuronal and mitochondrial membranes. This process favors cellular integrity, which is a core physiological requirement for neuronal communication and homeostasis.

---

Neurotransmitter and Synaptic Signaling Modulation

The extract influences nerve cell communication by regulating the availability of certain signaling molecules in the central nervous system. This is achieved through the partial inhibition of the Norepinephrine Transporter (NET) and modulation of Monoamine Oxidase A (MAO-A) enzyme activity. This mechanism contributes to a rebalancing of monoaminergic neurotransmission, regulating the signaling dynamics required for complex physiological processes.

Instruction Map: How to use Tebofortin — Official Administration Guidelines

Tebofortin, which contains a standardized Ginkgo biloba extract, is intended for oral administration using either solid (film-coated tablets) or liquid (oral solution) forms. The guidelines for its use are structured around the standard requirements for its administration.

Scope Item	Official Instruction
Route of administration	Oral use only (taken by mouth).
Dosing schedule	The standard daily dose of the standardized extract for adults is 120 mg to 240 mg. The highest regimen for certain applications is a daily dose of 240 mg.
Timing in relation to meals	The medicine is generally administered with meals or after food to facilitate intake.
Preparation requirements	Tablets are to be swallowed whole with water. Liquid forms require proper measurement using the provided dispenser and mixing with water prior to consumption.
Age-group administration rules	Use is limited to adults and the elderly. The product is explicitly not recommended for children and adolescents under 18 years of age.
Course duration for assessment	For age-related cognitive symptoms, the labeled protocol specifies that treatment should be reviewed if no improvement is observed after 3 months. For minor circulation symptoms, a review is advised if symptoms persist after 2 weeks.

Connection to the overall use protocol

These official instructions establish the standardized approach to medicine intake by confirming the oral route and setting the precise dose limits and frequency for daily administration. The regimen is designed exclusively for the adult population, and includes specific time points for assessing the duration of use, which ensures the usage adheres strictly to the established protocol.

Research evidence / Overview of studies for Tebofortin

Evidence for Age-Related Cognitive and Memory Issues

The standardized extract was evaluated in short-term Randomized Controlled Trials (RCTs), systematic reviews, and long-term observational studies involving older adults with mild cognitive impairment. Studies explored changes in global cognitive function using standardized scales. Long-term observational data reported patterns related to a less rapid change in some measured cognitive scores in subjects reporting extract use, compared to those who did not. However, two large RCTs monitored the incidence of dementia, and findings were mixed regarding changes in the rate of disease development.

Evidence for Peripheral Circulation Discomfort

Research primarily consists of controlled clinical trials and meta-analyses examining minor circulatory problems and physical discomfort in the limbs. Studies monitored objective outcomes, particularly measuring pain-free walking distance on a treadmill in individuals with Peripheral Arterial Occlusive Disease. Findings indicated a measured change in walking distance observed in some study groups, though subsequent independent research suggested the change measured was modest. Follow-up durations in these efficacy trials were typically limited to intermediate periods of under six months.

Evidence for Circulation-Related Sensory Symptoms

The extract was studied for its use in outcomes related to systemic imbalance, specifically addressing vertigo (dizziness) and tinnitus (ringing in the ears). Research examined short-term symptom changes using RCTs and patient-reported rating scales. Findings were mixed across the available evidence, and systematic reviews described the evidence base as limited and contradictory due to variations in study quality. Low-certainty evidence indicates that the study outcomes were minimal for the severity of tinnitus symptoms.

Research Gaps and Uncertainty

The body of research primarily focuses on older adults experiencing age-related changes; data for other specific subgroups remain insufficient. Several gaps exist, including mixed findings concerning the extract’s role in the long-term progression of cognitive decline in non-demented populations. Additionally, comparative evidence is lacking against other standard therapies in some areas, and evidence quality for sensory symptoms varies across studies.

Common questions about Tebofortin (FAQ)

Q: How quickly does Tebofortin start to show effects?

Studies and official information indicate that the review period for potential benefits is often set at four to six weeks of consistent use. This time frame helps determine if the medicine is achieving its intended support for age-related symptoms.

Q: What is the key difference between Tebofortin and other brain supplements?

Tebofortin is classified as a herbal medicinal product, meaning its regulatory oversight differs from that of standard food supplements. It contains the standardized EGb 761 extract, ensuring a consistent and quantified level of active compounds like flavonol glycosides and terpene lactones.

Q: Is there a certain time of day that is best to take Tebofortin?

Official administration guidelines state that the medicine should generally be taken with meals or after food to facilitate intake. The product information does not specify a particular time of day, such as morning or evening, as being superior for the medicine's effectiveness.

Q: Is Tebofortin considered a long-term treatment?

The length of time Tebofortin can be used is guided by regulatory bodies and may depend on the specific dose. For extended use beyond a defined initial assessment period, such as six weeks or eight months, official documentation indicates that specific consultation with a healthcare provider may be required.

Q: What are the signs of a possible allergic reaction to Tebofortin?

Official product information describes signs of an allergic reaction that may include skin rash, hives, itching, or swelling of the face, lips, tongue, or throat. If any of these signs appear, immediate professional medical attention should be sought.

Q: Can someone with high blood pressure use Tebofortin?

Official warnings state that individuals with high blood pressure should exercise caution. Specifically, if a person is already taking medication to manage this condition, official product information suggests consultation with a healthcare provider before starting this medicine.

Q: Where can I find the official product information sheet for Tebofortin?

The most complete source of official product information is the package leaflet that is supplied with the medicine itself. The official summary of product characteristics (SmPC) or other regulatory documents can also be obtained by contacting a pharmacist or doctor.

Q: Can Tebofortin be used by people with diabetes?

Official warnings suggest that individuals with diabetes or those taking related medication should seek the advice of a healthcare provider. This is because the medicine may potentially affect blood sugar levels, and close monitoring is recommended.

Q: What should I do if I notice an unusual side effect from Tebofortin?

If side effects are severe or life-threatening, such as symptoms of severe bleeding or an allergic reaction, it is necessary to seek immediate medical attention. For side effects that are unusual or persist for more than a few days, consultation with a healthcare provider is generally recommended.

Q: Does taking Tebofortin make you tired or affect sleep?

Official safety summaries do not commonly list fatigue or significant sleep disturbance as known adverse reactions. However, side effects that may affect the central nervous system, such as dizziness, are reported and could influence alertness.

Q: Does Tebofortin affect liver function tests?

While changes to liver function tests are not commonly reported, studies have sometimes included the careful examination of liver and kidney function as a safety procedure. Official trial documentation indicates that patients with severe existing impairment to either hepatic (liver) or renal (kidney) function have been excluded from some clinical studies.

Q: What information is available about Tebofortin and driving?

Regulatory patient information warns that due to possible side effects like dizziness, this medicine may temporarily affect a person’s ability to drive or operate machinery. Patients are generally advised to observe how the medicine affects them before engaging in activities requiring focus.

Q: Does Tebofortin have an impact on blood sugar levels?

Official warnings have indicated that the active ingredient in Tebofortin may affect blood sugar levels. Official warnings suggest that patients who have diabetes ensure close monitoring of blood glucose readings while taking the medicine.

Q: Is it necessary to have a medical check-up before starting Tebofortin?

It is generally recommended to consult a healthcare provider or pharmacist before beginning use. This step helps to confirm that the medicine is appropriate for individual health needs and to avoid potential conflicts.

Q: Can Tebofortin affect the results of any medical tests?

Yes, regulatory warnings confirm that the medicine must be discontinued before surgical or dental procedures because of its effect on blood coagulation (blood clotting). In patients with diabetes, it is advised to note that the medicine may potentially influence the accuracy of blood sugar tests.

Q: Can people with kidney issues take Tebofortin?

Regulatory caution is advised for patients with existing kidney issues. Clinical trials have sometimes excluded individuals with severe impairment of renal (kidney) function for safety reasons. Official information suggests that individuals with existing kidney issues seek the advice of a healthcare provider.

How to Store and Dispose of Tebofortin

Official regulatory documents define strict environmental and handling requirements to maintain the quality and 3-year stability of Tebofortin.

---

Storage Conditions

Requirement	Official Instruction
Temperature Limit	Do not store above 25 C
Protection	Store in the original package to protect from moisture
Child Safety	Keep out of the sight and reach of children

️ Disposal Requirements

Regulations state there are no special requirements for disposing of the product itself. However, any unused, unwanted, or expired Tebofortin must be disposed of in accordance with local requirements for pharmaceutical waste to ensure safe environmental handling.